Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
A nucleosomal protein, high mobility group box 1 (HMGB1) is known to be a late mediator of sepsis. Dabrafenib is a B-Raf inhibitor and initially used for the treatment of metastatic melanoma therapy. Inhibition of HMGB1 and renewal of vascular integrity is appearing as an engaging therapeutic strategy in the administration of severe sepsis or septic shock. Here, we examined the effects of dabrafenib (DAB) on the modulation of HMGB1-mediated septic responses. DAB inhibited the release of HMGB1 and downregulated HMGB1-dependent inflammatory responses by enhancing the expressions of cell adhesion molecules (CAMs) in human endothelial cells. In addition, treatment with DAB inhibited the HMGB1 secretion by CLP and sepsis-related mortality and pulmonary injury. This study demonstrated that DAB could be alternative therapeutic options for sepsis or septic shock via the inhibition of the HMGB1 signaling pathway.
Abstract
A nucleosomal protein, high mobility group box 1 (HMGB1) is known to be a late mediator of sepsis. Dabrafenib is a B-Raf inhibitor and initially used for the treatment of metastatic melanoma therapy. Inhibition of HMGB1 and renewal of vascular integrity is appearing as an engaging therapeutic strategy in the administration of severe sepsis or septic shock. Here, we examined the effects of dabrafenib (DAB) on the modulation of HMGB1-mediated septic responses. DAB inhibited the release of HMGB1 and downregulated HMGB1-dependent inflammatory responses by enhancing the expressions of cell adhesion molecules (CAMs) in human endothelial cells. In addition, treatment with DAB inhibited the HMGB1 secretion by CLP and sepsis-related mortality and pulmonary injury. This study demonstrated that DAB could be alternative therapeutic options for sepsis or septic shock via the inhibition of the HMGB1 signaling pathway.
참고문헌 (32)
- Russell JA, "Management of sepsis", N Engl J Med, 355, pp.1699~1713 (2006)
- Andreu Ballester JC, "Epidemiology of sepsis in the Valencian Community (Spain), 1995-2004", Infect Control Hosp Epidemiol, 29, pp.630~634 (1995)
- Angus DC, "Epidemiology of sepsis: an update", Crit Care Med, 29, pp.S109~S116 (2001)
- Bernard GR, "Efficacy, safety of recombinant human activated protein C for severe sepsis", N Engl J Med, 344, pp.699~709 (2001)
- "Br J Haematol", 2012, 493~494
- Bhatia M, "Sepsis as a model of SIRS", Front Biosci, 14, pp.4703~4711 (2009)
- Tracey KJ, "Anti-cachectin", TNF monoclonal antibodies prevent septic shock during lethal bacteraemia, 1987, pp.330, 662~664
- Wang H, "HMGB1 as a late mediator of lethal systemic inflammation", Am J Respir Crit Care Med, 164, pp.1768~1773 (2001)
- Bianchi ME, "HMG proteins: dynamic players in gene regulation, differentiation", Curr Opin Genet Dev, 15, pp.496~506 (2005)
- Ulloa L, "The "cytokine profile": a code for sepsis", Trends Mol Med, 11, pp.56~63 (2005)
- Bae JS, "Activated protein C inhibits high mobility group box 1 signaling in endothelial cells", Blood, 118, pp.3952~3959 (2011)
- Sunden-Cullberg J, "Persistent elevation of high mobility group box-1protein(HMGB1)in patients with severe sepsis, septic shock", Crit Care Med, 33, pp.564~573 (2005)
- Gibot S, "High-mobility group box 1 protein plasma concentrations during septic shock", Intensive Care Med, 33, pp.1347~1353 (2007)
- 배종섭, "Role of High Mobility Group Box 1 in Inflammatory Disease: Focus on Sepsis", Archives of Pharmacal Research, 35(9), pp.1511~1523 (2012), 대한약학회
- Li JX, "The B-Raf(V600E)inhibitor dabrafenib selectively inhibits RIP3, alleviates acetaminophen-induced liver injury", Cell Death Dis, 5, pp.e1278~ (2014)
- Padhy BM, "Drug repositioning: re-investigating existing drugs for new therapeutic indications", J Postgrad Med, 57, pp.153~160 (2011)
- Liu X, "Predicting targeted polypharmacology for drug repositioning, multi-target drug discovery", Curr Med Chem, 20, pp.1646~1661 (2013)
- O'Connor KA, "Finding new tricks for old drugs: an efficient route for public-sector drug discovery", Nat Rev Drug Discov, 4, pp.1005~1014 (2005)
- van Beijnum JR, "Convergence, amplification of toll-like receptor(TLR)and receptor for advanced glycation end products(RAGE)signaling pathways via high mobility group B1(HMGB1)", Angiogenesis, 11, pp.91~99 (2008)
- El Gazzar M, "HMGB1 modulates inflammatory responses in LPS-activated macrophages", Inflamm Res, 56, pp.162~167 (2007)
- Mullins GE, "Activation of human umbilical vein endothelial cells leads to relocation, release of high-mobility group box chromosomal protein 1", Scand J Immunol, 60, pp.566~573 (2004)
- Czura CJ, "High mobility group box-1 as a therapeutic target downstream of tumor necrosis factor", J Infect Dis, 187(Suppl 2), pp.S391~S393 (2003)
- Diehl KH, "A good practice guide to the administration of substances, removal of blood, including routes, volumes", J Appl Toxicol, 21, pp.15~23 (2001)
- Lee W, "Anti-septic effects of glyceollins in HMGB1-induced inflammatory responses in vitro, in vivo", Food Chem Toxicol, 63, pp.1~8 (2014)
- Qin YH, "HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products", J Immunol, 183, pp.6244~6250 (2009)
- Sun C, "Advanced glycation end products depress function of endothelial progenitor cells via p38, ERK 1", 2 mitogen-activated protein kinase pathways, 2009, pp.104, 42~49
- Palumbo R, "Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation", J Cell Biol, 179, pp.33~40 (2007)
- Luo Y, "HMGB1induces an inflammatory response in endothelial cells via the RAGE-dependent endoplasmic reticulum stress pathway", Biochem Biophys Res Commun, 438, pp.732~738 (2013)
- Erlandsson Harris H, "Mini-review : The nuclear protein HMGB1 as a proinflammatory mediator", Eur J Immunol, 34, pp.1503~1512 (2004)
- Park JS, "High mobility group box 1 protein interacts with multiple Tolllike receptors", Am J Physiol Cell Physiol, 290, pp.C917~C924 (2006)
- Yang EJ, "Barrier protective effects of rosmarinic acid on HMGB1-induced inflammatory responses in vitro, in vivo", J Cell Physiol, 228, pp.975~982 (2013)
- Astiz ME, "Septic shock", Lancet, 351, pp.1501~1505 (1998)